TTR and amyloidosis: The first FDA-approved LNP delivery system using ionizable lipids (e.g., 1,2-dilinoleyl-N,N-dimethyl-3-aminopropane) was designed to use RNAi to treat transthyretin-mediated amyloidosis.157